Chairman of the Supervisory Board
Mark Wegter joined our Board in 2001 as a representative of LSP, where he is a Managing Partner. He has been the company’s Chairman since. Prior to joining LSP, Mark worked as a Senior Analyst at ING Corporate and Investment Banking. Mark brings 20 years of hands-on finance, investment and board experience in the biotechnology sector to the Kiadis team, playing an active role in its growth and strategic direction. For the past 10 years, he has focused his professional attention to investing in publicly listed biotech companies that fall within the small- and mid-cap segment, building a track record of taking positions in undervalued companies and holding on to them long term. Mark holds a Master’s degree in Business Economics from the Erasmus University of Rotterdam.
Vice-Chairman of the Supervisory Board and Chairman of the Supervisory Board’s Audit Committee
Mr. Modig graduated from the University of Lund, Sweden, with a degree in business administration, economics and German, and received his M.B.A. from INSEAD, Fontainebleau, France. Mr. Modig became a member of our Supervisory Board in 2016. Mr. Modig was previously Chief Financial Officer of Prosensa Holding N.V. and before that Chief Financial Officer at Jerini AG. He is now also a Board Member of Axovant Sciences Ltd. and Affimed N.V., and CEO of Pharvaris B.V.
Supervisory Board Member, Chairman of the Supervisory Board’s Nomination and Remuneration Committee and member of the Supervisory Board’s Audit Committee
Mr. Kleijwegt became a member of our Supervisory Board in 2006. Mr. Kleijwegt graduated from the University of Amsterdam, The Netherlands, with a degree in economics. Mr. Kleijwegt founded Life Sciences Partners in 1998 and has been managing partner of Life Sciences Partners since that date.
Supervisory Board Member
Dr. Soiffer graduated from the New York University School of Medicine, United States of America and trained in internal medicine at Brigham and Women’s Hospital, where he also was chief medical resident. He joined the Dana-Farber Cancer Institute (DFCI) in 1988, after completing a medical oncology fellowship. Dr. Soiffer is a medical oncologist and Professor of Medicine at the Harvard Medical School, Chief of the Division of Hematologic Malignancies at the Dana-Farber Cancer Institute DFCI and Co-director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute DFCI.
Supervisory Board Member and member of the Supervisory Board’s Audit Committee
Dr. Otto Schwarz is a highly accomplished industry veteran, with significant operational and commercial leadership experience, including global launches of multiple major orphan and specialty care products. Most recently, Otto was Executive Vice-President, Chief Operating Officer and a member of the Actelion Executive Committee, up to the recent acquisition of Actelion by Johnson & Johnson.
Supervisory Board Member and member of the Supervisory Board’s Nomination and Remuneration Committee
Subhanu Saxena is currently a Regional Director with The Bill & Melinda Gates Foundation as well as partner New Rhein Healthcare and Senior Advisor to Bain Capital. He served, until recently, as the Managing Director and Global Chief Executive Officer of Cipla, a publicly listed, Indian pharmaceutical and biotech company, and was with Cipla from February 2013 to February 2017. Prior to joining Cipla, he was Head of Global Product Strategy and Commercialisation and member of the Executive Committee at Novartis. Mr. Saxena also previously served as CEO of Novartis UK.